Prioritize cardiac monitoring for high-risk breast cancer patients

August 6, 2018, American College of Cardiology

Overall, heart failure is an uncommon complication of breast cancer treatment; however, the risk is higher in patients treated with certain types of chemotherapy and lower in younger patients, according to a study in a special "Imaging in Cardio-oncology" issue of JACC: Cardiovascular Imaging. Researchers concluded that cardiac monitoring should be a higher priority for high-risk patients.

Cardiovascular disease is the second leading cause of death of survivors, behind secondary malignancies, due in part to the cardiac toxicities of some cancer therapies. However, little is known about the rate of chemotherapy-related cardiotoxicity and the rate of cardiac monitoring adherence among breast cancer treated with chemotherapy.

In this study, cardiotoxicity was defined as an incident case of heart failure following a breast cancer diagnosis. The study included 16,456 patients with a median age of 56 years who were treated with chemotherapy within six months of their diagnosis. Of those, 4,325 patients received trastuzumab-based chemotherapy.

Trastuzumab-based chemotherapy is a common treatment for patients with HER2-positive breast cancer, a very aggressive type of . It has consistently been shown to benefit patients, but it is also associated with cardiotoxicity.

The study found that 8.3 percent of the trastuzumab-treated patients developed heart failure versus 2.7 percent of patients who did not receive trastuzumab. Among patients who were treated with trastuzumab, 46.2 percent received guideline-adherent cardiac monitoring, which according to the National Comprehensive Cancer Network, is before initiating treatment and every three months while on the treatment. Researched also saw that as age increased, there was a consistent increase in the risk of heart failure.

This was the first study of its kind to estimate cardiotoxicity rates and cardiac monitoring using data on both younger and older women from the MarketScan database. Previous studies focused on older women who have higher rates of than reported in clinical trials, but this study focused more on younger women, who usually have fewer comorbidities and are similar to patients in previous trastuzumab trials. Younger women may receive more aggressive because they have a longer life expectancy, making them an important group to study for cardiac toxicity and cardiac monitoring.

Researchers said there could be many explanations for the low rates of cardiac monitoring seen in the patients treated with trastuzumab, including a low perceived need on the part of the physicians, rather than an unawareness of the guidelines.

"We must remember that while cardiac monitoring is recommended in different guidelines, such recommendations are not based on category 1 data, and the timing recommended, and the intervals of testing are rather arbitrary," said Mariana L. Henry, lead author of the study and a graduate student at Yale School of Public Health. "In examining the rate of both cardiac and cardiotoxicity we could begin to address the controversial issue of whether is warranted in young ."

Explore further: Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age

Related Stories

Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age

April 19, 2016
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute ...

Trastuzumab: No negative impact on cardiac function

January 3, 2018
Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal ...

Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

December 6, 2017
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...

More heart problems with two chemo drugs for breast cancer

August 30, 2012
Women who have breast cancer and are treated with two chemotherapy drugs may experience more cardiac problems like heart failure than shown in previous studies, according to a new Cancer Research Network study by Group Health ...

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects

May 17, 2018
A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free ...

Popular heart medications can prevent Herceptin-induced heart issues in some patients

March 12, 2018
Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab—a targeted cancer therapy that has been linked to heart damage—received no benefit in terms ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.